Czech Nationwide Financial institution raised its holdings in Edwards Lifesciences Co. (NYSE:EW – Free Report) by 6.9% within the third quarter, in accordance with its most up-to-date Type 13F submitting with the Securities & Change Fee. The institutional investor owned 122,715 shares of the medical analysis firm’s inventory after buying an extra 7,883 shares throughout the interval. Czech Nationwide Financial institution’s holdings in Edwards Lifesciences have been price $8,098,000 on the finish of the latest reporting interval.
A number of different giant buyers have additionally not too long ago modified their holdings of EW. Crewe Advisors LLC purchased a brand new place in shares of Edwards Lifesciences within the first quarter valued at roughly $28,000. First Group Belief NA purchased a brand new place in shares of Edwards Lifesciences within the second quarter valued at roughly $29,000. Riverview Belief Co purchased a brand new place in shares of Edwards Lifesciences within the first quarter valued at roughly $34,000. Webster Financial institution N. A. purchased a brand new place in shares of Edwards Lifesciences within the second quarter valued at roughly $39,000. Lastly, Rise Advisors LLC boosted its place in shares of Edwards Lifesciences by 125.0% within the first quarter. Rise Advisors LLC now owns 477 shares of the medical analysis firm’s inventory valued at $46,000 after buying an extra 265 shares throughout the interval. Hedge funds and different institutional buyers personal 79.46% of the corporate’s inventory.
Insider Shopping for and Promoting
In different Edwards Lifesciences information, VP Donald E. Bobo, Jr. bought 5,000 shares of the enterprise’s inventory in a transaction on Wednesday, August 14th. The shares have been bought at a median value of $66.08, for a complete transaction of $330,400.00. Following the transaction, the vice chairman now immediately owns 46,936 shares of the corporate’s inventory, valued at roughly $3,101,530.88. The commerce was a 0.00 % lower of their place. The sale was disclosed in a doc filed with the Securities & Change Fee, which may be accessed by the SEC web site. In different Edwards Lifesciences information, VP Donald E. Bobo, Jr. bought 5,000 shares of the enterprise’s inventory in a transaction on Wednesday, August 14th. The shares have been bought at a median value of $66.08, for a complete transaction of $330,400.00. Following the transaction, the vice chairman now immediately owns 46,936 shares of the corporate’s inventory, valued at roughly $3,101,530.88. The commerce was a 0.00 % lower of their place. The sale was disclosed in a doc filed with the Securities & Change Fee, which may be accessed by the SEC web site. Additionally, VP Daveen Chopra bought 1,250 shares of the enterprise’s inventory in a transaction on Tuesday, August twentieth. The shares have been bought at a median value of $69.95, for a complete transaction of $87,437.50. Following the transaction, the vice chairman now immediately owns 29,333 shares within the firm, valued at roughly $2,051,843.35. The commerce was a 0.00 % lower of their possession of the inventory. The disclosure for this sale may be discovered right here. Insiders have bought a complete of 11,250 shares of firm inventory valued at $751,688 during the last three months. 1.29% of the inventory is owned by firm insiders.
Analyst Upgrades and Downgrades
A variety of analysis corporations have not too long ago commented on EW. StockNews.com lowered shares of Edwards Lifesciences from a “purchase” score to a “maintain” score in a analysis report on Thursday, July twenty fifth. TD Cowen lowered shares of Edwards Lifesciences from a “purchase” score to a “maintain” score and dropped their goal value for the corporate from $100.00 to $70.00 in a analysis report on Thursday, July twenty fifth. Deutsche Financial institution Aktiengesellschaft dropped their goal value on shares of Edwards Lifesciences from $103.00 to $85.00 and set a “purchase” score for the corporate in a analysis report on Thursday, July twenty fifth. Robert W. Baird lowered shares of Edwards Lifesciences from an “outperform” score to a “impartial” score and dropped their goal value for the corporate from $102.00 to $70.00 in a analysis report on Thursday, July twenty fifth. Lastly, Wolfe Analysis upgraded shares of Edwards Lifesciences from an “underperform” score to a “peer carry out” score in a analysis report on Monday, July twenty ninth. Sixteen analysts have rated the inventory with a maintain score, eleven have issued a purchase score and one has given a powerful purchase score to the corporate. In accordance with knowledge from MarketBeat.com, the corporate presently has a median score of “Maintain” and a consensus goal value of $77.27.
Get Our Newest Inventory Evaluation on EW
Edwards Lifesciences Inventory Up 0.4 %
Shares of NYSE EW opened at $68.26 on Friday. The corporate has a fast ratio of two.87, a present ratio of three.71 and a debt-to-equity ratio of 0.08. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week excessive of $96.12. The agency’s fifty day shifting common is $66.86 and its 200 day shifting common is $80.43. The corporate has a market cap of $41.13 billion, a price-to-earnings ratio of 29.42, a PEG ratio of two.80 and a beta of 1.13.
Edwards Lifesciences (NYSE:EW – Get Free Report) final issued its earnings outcomes on Wednesday, July twenty fourth. The medical analysis firm reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a web margin of 24.55% and a return on fairness of twenty-two.35%. The corporate had income of $1.63 billion for the quarter, in comparison with the consensus estimate of $1.65 billion. Throughout the identical interval within the earlier yr, the agency earned $0.66 earnings per share. The agency’s income for the quarter was up 6.7% on a year-over-year foundation. On common, equities analysis analysts anticipate that Edwards Lifesciences Co. will publish 2.71 earnings per share for the present yr.
Edwards Lifesciences Profile
Edwards Lifesciences Company supplies merchandise and applied sciences for structural coronary heart illness and important care monitoring in the US, Europe, Japan, and internationally. It provides transcatheter coronary heart valve substitute merchandise for the minimally invasive substitute of aortic coronary heart valves underneath the Edwards SAPIEN household of valves system; and transcatheter coronary heart valve restore and substitute merchandise to deal with mitral and tricuspid valve illnesses underneath the PASCAL PRECISION and Cardioband names.
Additional Studying
Obtain Information & Scores for Edwards Lifesciences Day by day – Enter your e mail deal with beneath to obtain a concise day by day abstract of the newest information and analysts’ scores for Edwards Lifesciences and associated firms with MarketBeat.com’s FREE day by day e mail publication.
